Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.